Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain
Chugai Pharmaceutical and Biofourmis have partnered to continue developing digital solutions to measure pain in patients with endometriosis using a biosensor and an AI-based algorithm. The collaboration will focus on the continued development of pain measurement technology for endometriosis patients, advancing a technology platform for real-world data-driven pain measurement, and virtual specialty care delivery for endometriosis patients in the US. The partnership will also utilize data collected during research and development and post-marketing of Chugai's investigational product for the treatment of endometriosis pain. This collaboration aims to enhance Chugai's value proposition for endometriosis patients and deliver new value to patients as part of the company's growth strategy.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
